<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129245</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU FAMPLAN SFP3-7</org_study_id>
    <nct_id>NCT01129245</nct_id>
  </id_info>
  <brief_title>The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation</brief_title>
  <official_title>The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect that Celebrex (a COX-2 inhibitor and
      non-steroidal anti-inflammatory drug) has on ovulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized double-blind crossover study of healthy reproductive-aged (18-35
      years old) women with regular cycles, not currently using or needing hormonal contraception,
      were recruited. Women will undergo ovarian ultrasound and serum hormone monitoring during
      four menstrual cycles (control cycle, treatment cycle 1, washout cycle, treatment cycle 2).
      Subjects received study drug (oral celecoxib 400 mg or placebo) either 1) once daily starting
      on cycle day 8 and continuing until follicle rupture or the onset of next menses if follicle
      rupture did not occur (pre-LH surge dosing) or 2) once daily beginning with the LH surge and
      continued for 6 days (post-LH surge dosing). Women will be randomly assigned to one of the
      above treatment schemes and received the other in the subsequent treatment cycle.

      This study aims to determine if treatment with a highly selective COX2 inhibitor, celecoxib,
      would be a more effective agent in terms of causing ovulatory dysfunction. This study also
      aims to determine whether treatment with celecoxib would adversely affect luteal function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase</measure>
    <time_frame>4 cycles (approximately 4 months)</time_frame>
    <description>One cycle corresponds to one participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Hormone Levels</measure>
    <time_frame>4 cycles (approximately 4 months)</time_frame>
    <description>Average serum levels of progesterone (ng/mL) and luteinizing hormone (ng/mL) normalized to days of the luteal phase of menstrual cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Estradiol Level</measure>
    <time_frame>4 cycles (approximately 4 months)</time_frame>
    <description>Average serum levels of estradiol (pg/mL) normalized to days of the luteal phase of menstrual cycle.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ovulation</condition>
  <condition>Luteal Development</condition>
  <arm_group>
    <arm_group_label>Control cycle</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control menstrual cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-LH surge celecoxib administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-LH surge dosing of celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-LH surge celecoxib administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-LH surge dosing of celecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>400 mg PO daily intermittently based on hormone and ultrasound findings</description>
    <arm_group_label>Post-LH surge celecoxib administration</arm_group_label>
    <arm_group_label>Pre-LH surge celecoxib administration</arm_group_label>
    <other_name>Celecoxib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical to celecoxib</description>
    <arm_group_label>Post-LH surge celecoxib administration</arm_group_label>
    <arm_group_label>Pre-LH surge celecoxib administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-35

          -  Currently NOT using hormonal contraception

          -  Cycle length between 26-34 days

          -  General good health (specifically no hx of: diabetes, cardiac problems,
             moderate/severe heart burn (GERD), obesity (BMI &gt; 30), hypertension (BP &gt; 130/80)

          -  Willing and able to agree to randomization and informed consent

          -  Willing and able to use a menstrual diary to chart bleeding Serum progesterone &gt; 3
             ng/ml (from cycle day 18-25)

          -  Willing and able to return to clinic for bi-weekly for blood tests and ultrasounds
             throughout cycles 2, 3 &amp; 5

        Exclusion Criteria:

          -  Diabetes

          -  Cardiac disease

          -  Moderate to severe heart burn (or GERD) Obesity (BMI &gt; 30) Hypertension (BP &gt; 130/80)

          -  Allergy to NSAIDS

          -  Currently pregnant or trying to conceive

          -  Polycystic Ovarian Syndrome

          -  Use of hormonal contraception (participants can use barrier methods, spermicide,
             female or male sterilization, copper intrauterine device, abstinence, or have female
             partners
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040982/</url>
    <description>Author Manuscript</description>
  </link>
  <results_reference>
    <citation>Edelman AB, Jensen JT, Doom C, Hennebold JD. Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women. Contraception. 2013 Mar;87(3):352-7. doi: 10.1016/j.contraception.2012.07.004. Epub 2012 Aug 16.</citation>
    <PMID>22902348</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>April 7, 2014</results_first_submitted>
  <results_first_submitted_qc>June 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>Assistant Professor SM.OB/GYN Generalist Division</investigator_title>
  </responsible_party>
  <keyword>Celebrex</keyword>
  <keyword>prostoglandin inhibitor</keyword>
  <keyword>ovulation</keyword>
  <keyword>emergency contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PreLH Followed by postLH</title>
          <description>Control cycle First, preLH surge dosing of celecoxib and postLH surge dosing of placebo. Followed by, preLH surge dosing of placebo and postLH surge dosing of drug.</description>
        </group>
        <group group_id="P2">
          <title>PostLH Followed by preLH</title>
          <description>Control cycle First, postLH surge dosing of celecoxib and preLH surge dosing of placebo. Followed by, postLH surge dosing of placebo and preLH surge dosing of drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Control Cycle (no Celecoxib or Placebo)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Cycle 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Cycle</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Cycle 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>healthy reproductive-aged women with regular cycles, not currently using or needing hormonal contraception</population>
      <group_list>
        <group group_id="B1">
          <title>PreLH/postLH</title>
          <description>Control cycle First, preLH surge dosing of celecoxib and postLH surge dosing of placebo. Followed by, preLH surge dosing of placebo and postLH surge dosing of drug.</description>
        </group>
        <group group_id="B2">
          <title>PostLH/preLH</title>
          <description>Control cycle First, postLH surge dosing of celecoxib and preLH surge dosing of placebo. Followed by, postLH surge dosing of placebo and preLH surge dosing of drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.9"/>
                    <measurement group_id="B2" value="28.5" spread="4.9"/>
                    <measurement group_id="B3" value="27.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Non-Hispanic, Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase</title>
        <description>One cycle corresponds to one participant</description>
        <time_frame>4 cycles (approximately 4 months)</time_frame>
        <population>Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Cycle</title>
            <description>Monitoring through ovarian ultrasound and serum hormone levels of menstrual cycle prior to receiving any study treatment in order to insure ovulatory activity.</description>
          </group>
          <group group_id="O2">
            <title>Pre-LH Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
          <group group_id="O3">
            <title>Post-LH Surge Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results.
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cycles With Ovulation Dysfunction When Taken After Ovulation: Extended Luteal Phase</title>
          <description>One cycle corresponds to one participant</description>
          <population>Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Hormone Levels</title>
        <description>Average serum levels of progesterone (ng/mL) and luteinizing hormone (ng/mL) normalized to days of the luteal phase of menstrual cycle.</description>
        <time_frame>4 cycles (approximately 4 months)</time_frame>
        <population>One cycle corresponds to one participant. Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Cycle</title>
            <description>Monitoring through ovarian ultrasound and serum hormone levels of menstrual cycle prior to receiving any study treatment in order to insure ovulatory activity.</description>
          </group>
          <group group_id="O2">
            <title>Pre-LH Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
          <group group_id="O3">
            <title>Post-LH Surge Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results.
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Hormone Levels</title>
          <description>Average serum levels of progesterone (ng/mL) and luteinizing hormone (ng/mL) normalized to days of the luteal phase of menstrual cycle.</description>
          <population>One cycle corresponds to one participant. Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LH (luteinizing hormone)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="25"/>
                    <measurement group_id="O2" value="46.2" spread="28.4"/>
                    <measurement group_id="O3" value="42.6" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P (progesterone)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3.3"/>
                    <measurement group_id="O2" value="13.5" spread="3.9"/>
                    <measurement group_id="O3" value="12.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Estradiol Level</title>
        <description>Average serum levels of estradiol (pg/mL) normalized to days of the luteal phase of menstrual cycle.</description>
        <time_frame>4 cycles (approximately 4 months)</time_frame>
        <population>One cycle corresponds to one participant. Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control Cycle</title>
            <description>Monitoring through ovarian ultrasound and serum hormone levels of menstrual cycle prior to receiving any study treatment in order to insure ovulatory activity.</description>
          </group>
          <group group_id="O2">
            <title>Pre-LH Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
          <group group_id="O3">
            <title>Post-LH Surge Celecoxib</title>
            <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results.
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Estradiol Level</title>
          <description>Average serum levels of estradiol (pg/mL) normalized to days of the luteal phase of menstrual cycle.</description>
          <population>One cycle corresponds to one participant. Placebo treatment was not analyzed. This cycle was purely included in the study flow to keep investigators blinded to treatment allocation. It was pre-specified that it would not be analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274" spread="99.6"/>
                    <measurement group_id="O2" value="289.4" spread="124.5"/>
                    <measurement group_id="O3" value="282.2" spread="106.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control Cycle</title>
          <description>Monitoring through ovarian ultrasound and serum hormone levels of menstrual cycle prior to receiving any study treatment in order to insure ovulatory activity.</description>
        </group>
        <group group_id="E2">
          <title>Pre-LH Celecoxib</title>
          <description>Received Celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results.
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings.</description>
        </group>
        <group group_id="E3">
          <title>Post-LH Surge Celecoxib</title>
          <description>Receive celebrex at pre-determined time in menstrual cycle based on hormone levels and ultrasound results.
Celebrex: 400 mg PO daily intermittently based on hormone and ultrasound findings</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Edelman</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

